Understanding the role of TREM2 in liver disease progression.
Dissecting the Intracellular and Extracellular Role of TREM2 in the Pathogenesis of Non-Alcoholic Steatohepatitis.
This study is looking at how a protein called TREM2 affects the liver condition known as non-alcoholic steatohepatitis (NASH) to help understand why some people with fatty liver get worse while others don’t, with the hope of finding new ways to treat NASH.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Sanford Burnham Prebys Medical Discovery Institute NIH-funded |
| Lab location | 1 site (La Jolla, United States) |
| Project ID | NIH-11128281 on NIH RePORTER |
What this research studies
This research investigates how TREM2, a receptor found on immune cells, influences the development of non-alcoholic steatohepatitis (NASH), a serious liver condition. By studying both the intracellular and extracellular functions of TREM2, the researchers aim to uncover why some individuals with fatty liver progress to NASH while others do not. The study involves analyzing serum levels of a soluble form of TREM2 and its effects on inflammation and liver health. Patients may benefit from insights that could lead to new treatment strategies for NASH.
Who could benefit from this research
Good fit: Ideal candidates for this research include individuals diagnosed with non-alcoholic fatty liver disease (NAFLD) or non-alcoholic steatohepatitis (NASH).
Not a fit: Patients with liver diseases caused by alcohol consumption or other non-metabolic factors may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new therapeutic approaches for treating non-alcoholic steatohepatitis and preventing its progression to liver cancer.
How similar studies have performed: While the role of TREM2 in liver disease is being explored, this specific approach to understanding its protective mechanisms in NASH is relatively novel.
Where this research is happening
La Jolla, United States
- Sanford Burnham Prebys Medical Discovery Institute — La Jolla, United States (Active)
Researchers
- Principal investigator: Dhar, Debanjan — Sanford Burnham Prebys Medical Discovery Institute
- Study coordinator: Dhar, Debanjan
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.